These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38125917)

  • 1. HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation.
    Graeser M; Gluz O
    Breast Care (Basel); 2023 Dec; 18(6):455-463. PubMed ID: 38125917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
    Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
    J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer.
    Martínez-Sáez O; Waks AG
    Curr Treat Options Oncol; 2023 May; 24(5):479-495. PubMed ID: 36995527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer.
    Barot SV; Roesch E; Abraham J
    Expert Rev Anticancer Ther; 2022 Dec; 22(12):1289-1299. PubMed ID: 36373394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S12-S16. PubMed ID: 35148934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-escalation, and Future Prospects.
    Hashem M; Rehman S; Salhab M
    Cureus; 2024 Feb; 16(2):e55230. PubMed ID: 38558735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.
    Debien V; Adam V; Coart E; Agostinetto E; Goulioti T; Molinelli C; Arahmani A; Zoppoli G; Piccart M
    Future Oncol; 2023 Aug; 19(24):1655-1667. PubMed ID: 37609714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Pernas S; Tolaney SM
    JCO Oncol Pract; 2021 Jun; 17(6):320-330. PubMed ID: 34111378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer.
    Hong J; Park YH
    Ther Adv Med Oncol; 2022; 14():17588359221106564. PubMed ID: 35756967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
    Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
    Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
    Spring LM; Bar Y; Isakoff SJ
    J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.
    Foldi J; Rozenblit M; Park TS; Knowlton CA; Golshan M; Moran M; Pusztai L
    Curr Treat Options Oncol; 2021 Jul; 22(9):79. PubMed ID: 34213636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer.
    Abdel-Razeq H; Khalil H; Assi HI; Dargham TB
    Curr Oncol; 2022 Aug; 29(8):5810-5822. PubMed ID: 36005196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the status of neoadjuvant therapy in HER2-positive breast cancer.
    Dowling GP; Keelan S; Toomey S; Daly GR; Hennessy BT; Hill ADK
    Front Oncol; 2023; 13():1066007. PubMed ID: 36793602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies.
    Krawczyk N; Fehm T; Ruckhaeberle E; Brus L; Kopperschmidt V; Rody A; Hanker L; Banys-Paluchowski M
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.